ArticleACS nano2025
Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate Temporomandibular Joint Osteoarthritis by Suppressing Osteoclast Activity Via let-7a-5p/Integrin β3 Axis.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chondrogenic niche hydrogel microspheres facilitate cartilage regeneration in osteoarthritis.Bioactive materials · 2026Article
- MSC-EVs in Cartilage Regeneration and Immunomodulation: Mechanisms and Therapeutic Prospects for Osteoarthritis, Rheumatoid Arthritis and Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- Exercise‑induced exosomal noncoding RNAs: Molecular signaling cascades in bone remodeling and translational applications in sports‑related bone injuries (Review).International journal of molecular medicine · 2026Review
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporomandibular joint osteoarthritis (TMJOA) is a common degenerative oral disease and remains one of the most challenging joint disorders to treat clinically. It is characterized by excessive subchondral bone loss at an early stage and cartilage damage at a later stage. In recent years, mesenchymal stem cell (MSC) derived extracellular vesicles (MSC-EVs) have attracted widespread attention for their potential role in modulating OA pathology. However, the application of MSC-EVs in TMJOA remains underexplored, and the mechanisms underlying their therapeutic effects are not fully understood. In this study, we evaluate the therapeutic effects of human umbilical cord mesenchymal stem cell-derived extracellular vesicles (hUCMSC-EVs) on TMJOA, with a focus on subchondral bone, and investigate their underlying molecular mechanisms through miRNA sequencing. The results demonstrated that hUCMSC-EVs treatment significantly reduced osteoclast (OC) activity by transferring let-7a-5p, which further suppressed the expression of integrin β3 (ITGβ3) of osteoclasts. In a rat TMJOA model, intra-articular injection of hUCMSC-EVs demonstrated protective effects on both subchondral bone and cartilage, primarily through the suppression of osteoclast activity. Consequently, these results highlight the potential of hUCMSC-EV-based therapies as promising and effective approaches for the treatment of TMJOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.